A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence

Drug and Alcohol Dependence

Volumn 119, Issue 1-2, 2011, Pages

  Bisaga, Adam ^a   Sullivan, Maria A ^a   Cheng, Wendy Y ^a   Carpenter, Kenneth M ^a   Mariani, John J ^a   Levin, Frances R ^a   Raby, Wilfrid N ^a   Nunes, Edward V ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Naltrexone; NMDA receptors; Opiate dependence; Pharmacotherapy trials

Indexed keywords

DIAMORPHINE; MEMANTINE; METHADONE; NALTREXONE; OPIATE; PLACEBO; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; BODY ACHE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DETOXIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD INJURY; HOSPITALIZATION; HUMAN; HYPOTENSION; HYPOTENSION CRISIS; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA AND VOMITING; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK REDUCTION; SCORING SYSTEM; SOWS SCORE; SYNCOPE; TREATMENT DURATION; WEAKNESS; WITHDRAWAL SYNDROME;

ADULT; DISEASE PROGRESSION; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MEMANTINE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PLACEBOS; RECEPTORS, N-METHYL-D-ASPARTATE; RECURRENCE; SUBSTANCE ABUSE DETECTION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054994230     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.05.019     Document Type: Article

References (32)

1. Aguilar M.A., Manzanedo C., Do Couto B.R., Rodriguez-Arias M., Minarro J. Memantine blocks sensitization to the rewarding effects of morphine. Brain Res. 2009, 1288:95-104.
2. Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., Fischman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl.) 2001, 157:1-10.
3. Bisaga A., Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-d-aspartate (NMDA) antagonists. Drug Alcohol Depend. 2000, 59:1-15.
4. Brooks A.C., Comer S.D., Sullivan M.A., Bisaga A., Carpenter K.M., Raby W.M., Yu E., O'Brien C.P., Nunes E.V. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. J. Clin. Psychiatry 2010, 71:1371-1378.
5. Carroll K.M., Ball S.A., Nich C., O'Connor P.G., Eagan D.A., Frankforter T.L., Triffleman E.G., Shi J., Rounsaville B.J. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch. Gen. Psychiatry 2001, 58:755-761.
6. Collins E.D., Kleber H.D., Whittington R.A., Heitler N.E. Anesthesia-assisted vs. buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 2005, 294:903-913.
7. Collins E.D., Vosburg S.K., Ward A.S., Haney M., Foltin R.W. The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. Exp. Clin. Psychopharmacol. 2007, 15:228-237.
8. Comer S.D., Sullivan M.A. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology (Berl.) 2007, 193:235-245.
9. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev. 1997, 21:455-468.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2. 0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
11. Gass J.T., Olive M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem. Pharmacol. 2008, 75:218-265.
12. Haney M. Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict. Biol. 2009, 14:9-21.
13. Harris A.C., Rothwell P.E., Gewirtz J.C. Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia. Psychopharmacology (Berl.) 2008, 196:649-660.
14. Johansson B.A., Berglund M., Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 2006, 101:491-503.
15. Kornhuber J., Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. 1995, 195:137-139.
16. Krupitsky E.M., Masalov D.V., Burakov A.M., Didienko T.Y., Romanova T.N., Bespalov A.Y., Neznanov N.G. A pilot sudy of memantine effects on protracted withdrawal (syndrome of anhedonia) in heroin addicts. Addict. Disord. Their. Treat. 2002, 1:143-146.
17. Maldonado C., Cauli O., Rodriguez-Arias M., Aguilar M.A., Minarro J. Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal. Behav. Brain Res. 2003, 144:25-35.
18. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, CD002209.
19. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, CD002207.
20. Medvedev I.O., Dravolina O.A., Bespalov A.Y. Effects of N-methyl-d-aspartate receptor antagonists on discriminative stimulus effects of naloxone in morphine-dependent rats using the Y-maze drug discrimination paradigm. J. Pharmacol. Exp. Ther. 1998, 286:1260-1268.
21. Parsons C.G., Stoffler A., Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology 2007, 53:699-723.
22. Popik P., Danysz W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-d-aspartate receptor antagonist, memantine. J. Pharmacol. Exp. Ther. 1997, 280:854-865.
23. Popik P., Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 1996, 53:791-797.
24. Popik P., Wrobel M., Bisaga A. Reinstatement of morphine-conditioned reward is blocked by memantine. Neuropsychopharmacology 2006, 31:160-170.
25. Popik P., Wrobel M., Rygula R., Bisaga A., Bespalov A.Y. Effects of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforcers in mice. Behav. Pharmacol. 2003, 14:237-244.
26. Rammes G., Danysz W., Parsons C.G. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol. 2008, 6:55-78.
27. Ribeiro Do Couto B., Aguilar M.A., Manzanedo C., Rodriguez-Arias M., Minarro J. Effects of NMDA receptor antagonists (MK-801 and memantine) on the acquisition of morphine-induced conditioned place preference in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:1035-1043.
28. Ribeiro Do Couto B., Aguilar M.A., Manzanedo C., Rodriguez-Arias M., Minarro J. NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference. Brain Res. Bull. 2005, 64:493-503.
29. Rothenberg J.L., Sullivan M.A., Church S.H., Seracini A., Collins E., Kleber H.D., Nunes E.V. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J. Subst. Abuse Treat. 2002, 23:351-360.
30. Semenova S., Kuzmin A.V., Danysz W., Bespalov A.Y. Low affinity NMDA receptor channel blockers inhibit initiation of intravenous morphine self-administration in naive mice. Eur. J. Pharmacol. 1999, 378:1-8.
31. Skolnick P., Krystal J.H. Depression. Ionotropic Glutamate Receptors as Therapeutic Targets 2002, 71-90. F.P. Graham Publishing Co., Johnson City, TN. D. Lodge, W. Danysz, C. Parsons (Eds.).
32. Substance Abuse and Mental Health Services Administration Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings 2010, Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings, Rockville, MD.